Mostrar el registro sencillo del ítem
| dc.contributor.author | Ruiz-Irastorza, G | |
| dc.contributor.author | García, M | |
| dc.contributor.author | Espinosa, G | |
| dc.contributor.author | Caminal, L | |
| dc.contributor.author | Mitjavila, F | |
| dc.contributor.author | González-Leon, R | |
| dc.contributor.author | Sopena, B | |
| dc.contributor.author | Canora, J | |
| dc.contributor.author | Villalba, M-V | |
| dc.contributor.author | Rodríguez-Carballeira, M | |
| dc.contributor.author | López-Dupla, J-M | |
| dc.contributor.author | Callejas, J-L | |
| dc.contributor.author | Castro, A | |
| dc.contributor.author | Tolosa, C | |
| dc.contributor.author | Sánchez-García, M-E | |
| dc.contributor.author | Pérez-Conesa, M | |
| dc.contributor.author | Navarrete-Navarrete, N | |
| dc.contributor.author | Rodríguez, A-P | |
| dc.contributor.author | Herranz-Marín, María-Teresa | |
| dc.contributor.author | Pallares, L | |
| dc.date.accessioned | 2026-10-21T06:05:22Z | |
| dc.date.available | 2026-10-21T06:05:22Z | |
| dc.date.issued | 2016-08 | |
| dc.identifier.citation | Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. agosto de 2016;3(1):e000153. doi:10.1136/lupus-2016-000153 | |
| dc.identifier.issn | 2053-8790 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28695 | |
| dc.description.abstract | AIM: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). METHODS: 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). RESULTS: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2-12 dose (p<0.001). Compared with patients on no prednisone, patients taking medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or high-dose prednisone-1 (adjusted OR 10.5, 95% CI 3.8 to 29.17) were more likely to receive prednisone-2-12 doses of >7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ?6, the model did not change. CONCLUSION: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months. | |
| dc.language.iso | eng | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.title | First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 27547439 | |
| dc.relation.publisherversion | https://lupus.bmj.com/lookup/doi/10.1136/lupus-2016-000153 | |
| dc.identifier.doi | 10.1136/lupus-2016-000153 | |
| dc.journal.title | Lupus Science & Medicine |